News

A new major player in T cell suppression and tumor control

An inhibitory receptor binds a checkpoint protein to thwart T cell proliferation and function.
Written byLuisa Torres, PhD
| 3 min read
3D rendering of a therapeutic antibody molecule binding to PD-1 protein on a surface of a t cell.

The VISTA-LRIG1 axis impairs T cell activity and delays tumor growth.

credit: iStock.com/Marcin Klapczynski

Register for free to listen to this article
Listen with Speechify
0:00
3:00

Back in 2011, Cleveland Clinic researchers reported that the checkpoint protein V-domain immunoglobulin suppressor of T cell activation (VISTA) inhibited the T cell response when overexpressed on tumor cells and speculated that it would be a good cancer immunotherapy target (1). Over the next decade, the scientists focused on identifying VISTA's binding partners and signaling mechanisms.

LRIG1 single-handedly seems to be having a major effect if you knock it out,
– Li Lily Wang, Cleveland Clinic

In a new study, those same scientists now reported that the inhibitory receptor leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) inhibits T cell proliferation, survival, and effector function when bound to VISTA (2). The findings, published in Science Immunology, introduce a new target in the fight against cancer and offer a potential explanation for immunotherapy resistance or cancer recurrence.

“Identifying new immune checkpoints that also affect T cell activation is important so they can be targeted and lead to the development of new therapeutic strategies,” said Lionel Apetoh, an immunologist at Indiana University, who was not involved in the study.

During their search for VISTA’s binding partners, the team discovered LRIG1, a protein expressed on stem cells in both healthy and cancerous tissues (3). “But just because the protein binds doesn't mean it has any relevant function,” said Li Lily Wang, an immunologist at the Cleveland Clinic and study coauthor. “That's when the project started looking more and more promising because we found out that if we engaged LRIG1, T cells get shut down and the tumor gets controlled better because the tumor-reactive T cell response is enhanced.”

Continue reading below...
A 3D illustration of two sphericaA 3D illustration of two spherical cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.l cells in close contact, with glowing blue nuclei and additional out-of-focus cells in the background.
Application NoteRevealing cell-cell interactions in immuno-oncology
Imaging-enabled flow cytometry helps distinguish biologically relevant cell-cell interactions from coincident events to support immunotherapy research.
Read More
Li Lily Wang smiles at the camera in front of a plain and light-colored background.
Li Lily Wang’s research group studies the mechanisms by which the immune checkpoint protein VISTA modulates immune responses to tumors.
credit: Cleveland Clinic

Other scientists had identified other VISTA binding partners but none that directly caused T cell functional outcomes. “LRIG1 single handedly seems to be having a major effect if you knock it out,” said Wang.

The team confirmed LRIG1’s inhibitory role in in vitro and in vivo experiments, and in patient tumor samples. Compared to normal T cells, stimulated cultured T cells without LRIG1 or VISTA showed increased T cell receptor signaling. Stimulated T cells lacking LRIG1 showed greater expansion, higher cytokine production, and reduced cell death.

Within tumors overexpressing VISTA, wildtype T cells were significantly diminished, while T cells lacking LRIG1 were resistant to VISTA-mediated suppression. LRIG1 knockout mice had increased CD8+ tumor infiltrating lymphocyte expansion and improved effector function along with delayed tumor growth compared to wildtype animals.

In melanoma patients treated with immune checkpoint inhibitors, a significantly higher proportion of CD8+ tumor infiltrating lymphocytes expressed LRIG1 in those who did not respond to therapy compared to those who did.

In future work, Wang’s group plans to study whether LRIG1 binds to ligands other than VISTA and the exact downstream signaling mechanisms of LRIG1. They also plan to investigate whether one or more therapeutic reagents blocking the VISTA-LRIG1 axis show effective outcomes in tumor models.

“We have a relatively strong case to argue for this axis to be a very significant regulator of anti-tumor immunity,” Wang said. “There are a lot more follow-up studies to be done, and we're very excited about this direction.”

References

  1. Wang, L. et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med 208, 577–592 (2011).
  2. Ta, H. M. et al. LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses. Sci Immunol 9, eadi7418 (2024).
  3. Wang, Y., Poulin, E.J. & Coffey, R.J. LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer 108, 1765–1770 (2013).
Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

  • Luisa Torres

    Luisa is an assistant science editor at Drug Discovery News. She has a PhD in Molecular and Cellular Pharmacology from Stony Brook University where she researched anti-inflammatory treatments for spinal cord injury. Later, as a postdoctoral fellow, she studied how parasitic infections may lead to signs of Alzheimer’s disease. She has written for NPR’s blogs ‘Shots’, ‘The Salt ‘and ‘Goats and Soda’. Her interests include metabolism, aging and drug discovery.

    View Full Profile

Here are some related topics that may interest you:

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.